Onyx is again underperforming the other biotechs (CELG, AMGN, etc.)--although the day is not over yet. Perhaps we need some additional good news to propel this higher. They should have already reported the thyroid results. Any views on the delay?
I agree about the size of the thyroid market. The same point was made in a recent Morgan Stanley report. Why this weakness then, given all the recent buy recommendations with PT targets well over $90?